Stephen K. Doberstein

2013

In 2013, Stephen K. Doberstein earned a total compensation of $1.2M as Senior Vice President and Chief Scientific Officer at Nektar Therapeutics, a 7% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$231,000
Option Awards$459,370
Salary$459,722
Other$9,513
Total$1,159,605

Doberstein received $459.7K in salary, accounting for 40% of the total pay in 2013.

Doberstein also received $231K in non-equity incentive plan, $459.4K in option awards and $9.5K in other compensation.

Rankings

In 2013, Stephen K. Doberstein's compensation ranked 5,971st out of 12,286 executives tracked by ExecPay. In other words, Doberstein earned more than 51.4% of executives.

ClassificationRankingPercentile
All
5,971
out of 12,286
51st
Division
Manufacturing
2,071
out of 4,612
55th
Major group
Chemicals And Allied Products
606
out of 1,462
59th
Industry group
Drugs
436
out of 1,156
62nd
Industry
Pharmaceutical Preparations
350
out of 890
61st
Source: SEC filing on April 30, 2015.

Doberstein's colleagues

We found four more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2013.

2013

Howard Robin

Nektar Therapeutics

Chief Executive Officer

2013

John Nicholson

Nektar Therapeutics

Chief Financial Officer

2013

Gil Labrucherie

Nektar Therapeutics

General Counsel

2013

Rinko Ghosh

Nektar Therapeutics

Senior Vice President and Chief Business Officer

News

You may also like